View Clinical Trial (Medical Research Study)
AC6 Gene Transfer for Congestive Heart Failure - NCT00787059-92161(Clinical Trial 251694)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
San Diego |
|
State:
|
|
CA |
| Zip Code: |
|
92161 |
| Conditions: |
|
Congestive Heart Failure |
| Purpose: |
|
This research study is designed to determine: 1) whether gene transfer using an agent called
Ad5.hAC6 (adenovirus-5 encoding human adenylyl cyclase type 6) can be given safely to
patients with congestive heart failure (CHF) and 2) whether this agent may be of benefit in
heart failure. Gene transfer is an idea in which genes are introduced into cells and the
cells then produce the specific protein that the gene directs, in this case, a protein known
as adenylyl cyclase type 6 (AC6). The gene is carried into the heart cells by a modified
virus. The virus that is modified is an adenovirus (Ad5), a virus that sometimes causes a
brief cold. In extensive animal experiments, it was found that increased amounts of AC6
protein in heart cells appeared to make the heart pump more vigorously.
|
| Study summary: |
|
This research study is designed to determine: 1) whether gene transfer using an agent called
Ad5.hAC6 (adenovirus-5 encoding human adenylyl cyclase type 6) can be given safely to
patients with congestive heart failure (CHF) and 2) whether this agent may be of benefit in
heart failure. Gene transfer is an idea in which genes are introduced into cells and the
cells then produce the specific protein that the gene directs, in this case, a protein known
as adenylyl cyclase type 6 (AC6). The gene is carried into the heart cells by a modified
virus. The virus that is modified is an adenovirus (Ad5), a virus that sometimes causes a
brief cold. In extensive animal experiments, it was found that increased amounts of AC6
protein in heart cells appear to make the heart pump more vigorously. |
| Criteria: |
|
Inclusion Criteria
1. Male or non-pregnant female patients aged 18-80 years of age
2. ≥3-month history of heart failure
3. Compensated (stable) CHF not on intravenous inotropes, vasodilators or diuretics, on
optimal medical and device therapy as defined by AHA/ACC Guidelines
4. LV ejection fraction (on optimal therapy) no greater than 40%
5. Implanted cardiac defibrillator
6. At least one major coronary artery (or graft) with <50% proximal obstruction
7. Maximal exercise (in estimated METs) on treadmill testing must not exceed 65% of
age-predicted maximum [ Predicted METs = 15 - (Age/10) ]. Patients unable to walk
(spinal injury, orthopedic problems) can be enrolled if all other criteria are met.
8. Women of child-bearing capacity must have a negative pregnancy test within 2 days of
test substance administration, and female and male patients must be willing to use
birth control during sex for 12w after test substance administration if the female
partner is of child-bearing capacity.
9. Subjects willingly provide informed consent consistent with ICH-GCP guidelines
Exclusion Criteria
1. Unstable or Class IV angina
2. Coronary revascularization planned or predicted in next 6 months
3. Ischemic myocardium in 3 or more regions of a single perfusion bed, as assessed by
stress echocardiography or jeopardized viable myocardium >15% on perfusion imaging.
4. ≥50% occlusion of an "unprotected" left main coronary artery. If arterial or venous
conduits provide blood flow to the distal left coronary circulation (ie, patent
bypass grafts) then left main disease is "protected" and such patients are not
excluded. The cardiologist performing the cardiac catheterization will make these
decisions.
5. 2° AV Block (Mobitz 2) or 3° AV block unless pacemaker is present
6. Hospitalization for CHF requiring intravenous inotropes or vasodilators in the past 4
weeks
7. History of biopsy proven myocarditis
8. Myocardial infarction in previous 6 months
9. Restrictive, hypertrophic or infiltrative cardiomyopathy or chronic pericarditis
10. Previous or planned organ transplant recipient or donor.
11. Thrombocytopenia (<100,000 platelets/µl) or bleeding diathesis
12. COPD requiring supplemental oxygen at home
13. AST > 2 times upper limit of normal or chronic liver disease such as cirrhosis or
Hepatitis C Virus (HCV). Patients with HCV are eligible only if both of two
conditions are met: a) liver function tests are normal; AND b) liver biopsy is normal
or shows only mild fibrosis.
14. Current or predicted need for hemodialysis within 12 months or creatinine clearance
<30 ml/min, either estimated (MDRD equation) or measured
15. CVA or TIA <6 months prior to enrollment
16. Patients who are immunosuppressed by medicines (corticosteroids, methotrexate,
cyclophosphamide, cyclosporine), illnesses (AIDS, HIV), or neutrophil count <1000/mm3
17. Patients receiving other investigational drug therapy within 30 days of enrollment
including gene transfer
18. Serum anti-adenovirus-5 antibody titer >1:256, assessed by antibody neutralization
assay
19. Patients with diseases other than CHF that, in the opinion of the investigator, put
the subject at risk or adversely affect the results |
|
|
|
| Study is available at: |
|
VA San Diego Healthcare System San Diego, CA 92161 United States
Primary Contact: H. Kirk Hammond, MD Email: khammond@ucsd.edu Phone: 858-642-3542
Secondary Contact: H. Kirk Hammond, MD Email: khammond@ucsd.edu Phone: 858-642-3542 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|